Journal article
γT‐S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo
Abstract
BACKGROUND: Dabigatran etexilate (DE) is an oral direct thrombin inhibitor used to prevent strokes in patients with atrial fibrillation. No licensed DE antidote is currently available. We hypothesized that active site-mutated S195A thrombin (S195A-IIa) and/or its trypsinized derivative (γT -S195A-IIa) would sequester dabigatran, the active form of DE, and reduce its anticoagulant effects.
OBJECTIVE: To assess active site-mutated S195A or γT …
Authors
Sheffield WP; Lambourne MD; Eltringham‐Smith LJ; Bhakta V; Arnold DM; Crowther MA
Journal
Journal of Thrombosis and Haemostasis, Vol. 12, No. 7, pp. 1110–1115
Publisher
Elsevier
Publication Date
July 2014
DOI
10.1111/jth.12601
ISSN
1538-7933